The "Great Debate" at Melanoma Bridge 2022, Naples, December 1st-3rd, 2022.

J Transl Med · 2023 · PMC10114457 · PMID 37072748

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

not yet significantno p-value reported

As well as a significant EFS benefit with neoadjuvant over adjuvant therapy has been seen in this trial, the HR for OS (0.63) also favoured neoadjuvant, although is not yet significant.

also in 225 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.